Related Experiment Video
Updated: Jul 5, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
Published on: August 14, 2017
Genetic defects in von Willebrand disease type 3 in Indian and Greek patients
P K Gupta1, R Saxena, E Adamtziki
1Department of Transfusion Medicine, Haematology Section, Armed Forces Medical College, Pune-411040, India. paw_5671@hotmail.com
Insights
Von Willebrand disease type 3 is a severe bleeding disorder caused by diverse mutations in the VWF gene. Gene conversions and R1659X mutations are the most frequent molecular defects identified in Indian and Greek patients.
Area of Science:
- Genetics
- Hematology
- Molecular Biology
Background:
- Von Willebrand disease (VWD) type 3 is a severe, autosomal recessive bleeding disorder.
- It presents with a consistent phenotype but diverse underlying genetic causes.
- Understanding the molecular basis is crucial for diagnosis and management.
Purpose of the Study:
- To investigate the molecular basis of VWD type 3 in Indian and Greek populations.
- To identify specific mutations in the von Willebrand factor (VWF) gene.
- To correlate genotype with the severe VWD type 3 phenotype.
Main Methods:
- Screening of the complete VWF gene in 21 Indian and 6 Greek patients with VWD type 3.
- Utilizing Polymerase Chain Reaction (PCR) and direct sequencing of VWF exons and flanking introns.
- Analysis focused on identifying mutations and characterizing their nature (e.g., nonsense, deletions, insertions, gene conversions).
Main Results:
- VWD type 3 diagnosis confirmed by detecting null alleles or two mutations in 22 patients.
- Most identified defects resulted in null alleles (16 out of 23 patients).
- Common mutations included homozygous nonsense mutations (R1659X, W553X, L1267X) and gene conversions, particularly R1659X in exon 28.
Conclusions:
- VWD type 3 arises from a wide spectrum of mutations across the VWF gene.
- The majority of mutations (16/23) lead to null alleles, consistent with the severe phenotype.
- Gene conversions and the R1659X mutation were identified as the most prevalent molecular defects in this cohort.
Background:
Von Willebrand disease type 3 VWD is an autosomal-recessively inherited severe bleeding disorder with a homogeneous phenotype on the basis of very heterogeneous genotypes. Many different molecular defects have been reported to date. We tried to assess the molecular background of Indian and Greek patients with VWD type 3 by doing a complete VWF gene screen in all index patients.
Materials And Methods:
We investigated 21 unrelated Indian and six Greek patients with type 3 VWD. Mutation screening was done by PCR and direct sequencing of the coding VWF exons 2-52 including flanking intron sequences.
Results:
The diagnosis of VWD type 3 could be confirmed by the detection of null alleles or two mutations each in 22 patients. In one patient only one heterozygous mutation was identified. In four patients no mutations were identified for unknown reasons. Most of the defects cause null alleles. Eight patients had homozygous nonsense mutations - R1659X (6 patients), W553X (1 patients) and L1267X (1 patient); 2 patients were compound heterozygous - R324X/R373X and N318K/Q565X; 3 patients had small insertions - 3259insT, 3737insCC and 7173insT; 2 patients had small deletions - 3938delG and 1381delG; 2 patients had a duplication of 8 bp (duplAGTGTGGA) in exon 28 and a missense mutation (R273W) in exon 7; one patient had a heterozygous mutation K1794E (second mutation not identified); 5 patients had gene conversions between VWF and its pseudogene (117 bp to 335 bp in length corresponding to the 5' end of exon 28). The mutations as part of the gene conversion were - S1263P, P1266L, V1279I, Q1311X, A1317, I1343V, V1360A, and F1369I.
Conclusion:
VWD type 3 is caused by a broad variety of mutations distributed over the entire VWF sequence. As expected most mutations cause null alleles (16/23). The most common molecular defects found were gene conversions and R1659X in exon 28.
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Incomplete Dominance
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pedigree Analysis
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life